Subscribe
shutterstock_1548709493_nitpicker
nitpicker / Shutterstock.com
6 September 2021AmericasMuireann Bolger

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis (apixaban).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bristol Myers can’t convince circuit to overturn $1.2bn ruling
18 January 2022   The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
Big Pharma
Pfizer accuses ex-employees of stealing trade secrets for startup
3 February 2022   Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Bristol Myers can’t convince circuit to overturn $1.2bn ruling
18 January 2022   The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
Big Pharma
Pfizer accuses ex-employees of stealing trade secrets for startup
3 February 2022   Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

More on this story

Americas
Bristol Myers can’t convince circuit to overturn $1.2bn ruling
18 January 2022   The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
Big Pharma
Pfizer accuses ex-employees of stealing trade secrets for startup
3 February 2022   Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?